Mora S - Search Results

1

Monitoring of lipodystrophic and metabolic abnormalities in HIV-1 infected children on antiretroviral therapy.

Spoulou V, Kanaka-Gantenbein C, Bathrellou I, Mora S, Mostrou G, Sidossis L, Chrousos G, Theodoridou M. Spoulou V, et al. Among authors: mora s. Hormones (Athens). 2011 Apr-Jun;10(2):149-55. doi: 10.14310/horm.2002.1305. Hormones (Athens). 2011. PMID: 21724540 Free article.

2

Lipodystrophy, insulin resistance, and adiponectin concentration in HIV-infected children and adolescents.

Viganò A, Zuccotti GV, Cerini C, Stucchi S, Puzzovio M, Giacomet V, Mora S. Viganò A, et al. Among authors: mora s. Curr HIV Res. 2011 Jul;9(5):321-6. doi: 10.2174/157016211797635946. Curr HIV Res. 2011. PMID: 21827385

3

Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.

Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Viganò A. Mora S, et al. AIDS. 2001 Sep 28;15(14):1823-9. doi: 10.1097/00002030-200109280-00011. AIDS. 2001. PMID: 11579244

4

Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children.

Viganò A, Mora S, Testolin C, Beccio S, Schneider L, Bricalli D, Vanzulli A, Manzoni P, Brambilla P. Viganò A, et al. Among authors: mora s. J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):482-9. doi: 10.1097/00126334-200304150-00003. J Acquir Immune Defic Syndr. 2003. PMID: 12679698

5

Antiretroviral therapy and bone mineral measurements in HIV-infected youths.

Zuccotti G, Viganò A, Gabiano C, Giacomet V, Mignone F, Stucchi S, Manfredini V, Marinacci F, Mora S. Zuccotti G, et al. Among authors: mora s. Bone. 2010 Jun;46(6):1633-8. doi: 10.1016/j.bone.2010.02.029. Epub 2010 Mar 6. Bone. 2010. PMID: 20211284

6

A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children.

Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Viganò A. Giacomet V, et al. Among authors: mora s. J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):448-50. doi: 10.1097/01.qai.0000184860.62189.c8. J Acquir Immune Defic Syndr. 2005. PMID: 16280700

7

Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths.

Viganò A, Zuccotti GV, Puzzovio M, Pivetti V, Zamproni I, Cerini C, Fabiano V, Giacomet V, Mora S. Viganò A, et al. Among authors: mora s. Antivir Ther. 2010;15(7):1053-8. doi: 10.3851/IMP1650. Antivir Ther. 2010. PMID: 21041922

8

Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents.

Viganò A, Mora S, Brambilla P, Schneider L, Merlo M, Monti LD, Manzoni P. Viganò A, et al. Among authors: mora s. AIDS. 2003 Jul 4;17(10):1435-41. doi: 10.1097/00002030-200307040-00003. AIDS. 2003. PMID: 12824780

9

Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz.

Viganò A, Brambilla P, Cafarelli L, Giacomet V, Borgonovo S, Zamproni I, Zuccotti G, Mora S. Viganò A, et al. Among authors: mora s. Antivir Ther. 2007;12(3):297-302. Antivir Ther. 2007. PMID: 17591019 Clinical Trial.

10

Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz.

Fabiano V, Giacomet V, Viganò A, Bedogni G, Stucchi S, Cococcioni L, Mora S, Zuccotti GV. Fabiano V, et al. Among authors: mora s. Eur J Pediatr. 2013 Aug;172(8):1089-96. doi: 10.1007/s00431-013-2018-3. Epub 2013 May 1. Eur J Pediatr. 2013. PMID: 23636286 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

727 results

Search Page

Filters